Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label
Executive Summary
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.